US2020041521A1PendingUtilityA1
Cancer diagnosis and therapy
Assignee: GILIES MCINDOE RES INSTITUTEPriority: Aug 12, 2014Filed: Mar 4, 2019Published: Feb 6, 2020
Est. expiryAug 12, 2034(~8 yrs left)· nominal 20-yr term from priority
G01N 33/57557G01N 33/5759G01N 33/57595A61P 35/00A61K 45/00A61K 31/59A61K 33/06G01N 33/57496G01N 33/57407G01N 33/57492A61K 31/138A61K 31/40G01N 33/5758
44
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides a novel approach to cancer diagnosis and therapy of cancer by providing compositions and methods for the identification and specific targeting of the cancer stem cell populations present in a tumour to eradicate, or slow or prevent tumour (5) growth and spread, including the potential for tumour metastasis, by modulation of the Renin-Angiotensin System including, but not limited to, Renin Receptor, Angiotensin II Receptor (2) and a secreted form of the Renin Receptor.
Claims
exact text as granted — not AI-modified1 . A method for preventing, treating, or managing cancer in a patient in need thereof, the method comprising (a) detecting expression of OCT4, SOX2, NANOG, c-Myc, and KLF4 on cancer stem cells from the patient, and (b) administering one or more therapeutic agent(s) to the patient in an amount sufficient to selectively eradicate, or inhibit the growth, proliferation and/or differentiation of cancer stem cells in a tumour within the cancer, wherein the therapeutic agent is selected from the group consisting of Direct Renin Inhibitors (DRIs), Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin Receptor Blockers (ARBs), Beta-Blockers, Cyclo-oxygenase 2 Inhibitors, Chymase Inhibitors, Inhibitors of Cathepsin B, Cathepsin D and Cathepsin G, Calcium, Vitamin D, and Calcium Channel Blockers.
2 .- 5 . (canceled)
6 . A method according to claim 1 , wherein the cancer is selected from the group consisting of squamous cell carcinoma of the head and neck (including the upper aerodigestive tract), squamous cell carcinoma of the skin, melanoma, lung cancer, breast cancer, kidney cancer, brain cancer, bowel cancer, thyroid cancer, prostate cancer, lymphoma, leukemia and sarcomas.
7 . A method according to claim 6 , wherein the cancer is squamous cell carcinoma of the head and neck.
8 . A method according to claim 6 , wherein the squamous cell carcinoma of the head and neck is located in the aerodigestive track.
9 . A method for preventing, treating, or managing cancer in a patient in need thereof, the method comprising (a) detecting expression of SOX2, NANOG, c-Myc, and KLF4 on cancer stem cells from the patient, and (b) administering one or more therapeutic agents to the patient in an amount sufficient to selectively eradicate or inhibit the growth, proliferation and/or differentiation of cancer stem cells in a tumour associated with the cancer, wherein the therapeutic agent is selected from the group consisting of Direct Renin Inhibitors (DRIs), Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin Receptor Blockers (ARBs), Beta-Blockers, Cyclo-oxygenase 2 Inhibitors, Chymase Inhibitors, Inhibitors of Cathepsin B, Cathepsin D and Cathepsin G, Calcium, Vitamin D, and Calcium Channel Blockers.
10 .- 15 . (canceled)
16 . The method of claim 9 , wherein step (a) comprises detecting lack of expression of OCT4.
17 . The method according claim 9 , wherein the cancer is selected from the group consisting of squamous cell carcinoma of the head and neck, squamous cell carcinoma of the skin, melanoma, lung cancer, breast cancer, kidney cancer, brain cancer, bowel cancer, thyroid cancer, prostate cancer, lymphoma, leukemia and sarcomas.
18 . The method according to claim 9 , wherein the cancer is squamous cell carcinoma of the head and neck.
19 . The method according to claim 9 , wherein the squamous cell carcinoma of the head and neck is located in the aerodigestive tract.Join the waitlist — get patent alerts
Track US2020041521A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.